$OXIS Technology is Lightning in a Bottle

In his inaugural blog post, Oxis Chairman and Chief Executive Officer Anthony Cataldo, discusses the unmet medical need for effective treatment options for triple negative breast cancer (TNBC) and multiple myeloma. He offers a look into his past experience in leading an evolving biotech company to commercialize a product that has changed the lives of cancer patients and shares how he is advancing upon a similar opportunity with Oxis. Read the full blog post from Mr. Cataldo on TheChairmansBlog.com (https://www.thechairmansblog.com/oxis-international/anthony-cataldo/oxis-technology-is-lightning-in-a-bottle/).

About Oxis International, Inc.

Oxis International, Inc. through its wholly owned subsidiary Oxis Biotech, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. OXIS’ lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com